Moderna (MRNA) Shares Drop 8% despite Impressive Result from Cancer Vaccine Phase 2 Trial
With the second part concluded, the Section 3 melanoma trial will start quickly. Biotechnology firm Moderna Inc (NASDAQ: MRNA) skilled shares decline on Monday as an replace on its most….